biostudies-literatureUnknown380Mao YPNatural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of China<h4>Objectives</h4>To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma.<h4>Design</h4>Open-label, non-inferiority, multicentre, randomised, phase 3 trial.<h4>Setting</h4>Three Chinese hospitals between 20 November 2017 and 3 December 2018.<h4>Participants</h4>Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement.<h4>Interventions</h4>Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer Center. Eligible patients were randomly assigned (1:1; block size of four) to receive MRLN sparing radiotheBMJ (Clinical research ed.)e072133https://www.ebi.ac.uk/biostudies/studies/S-EPMC9900470biostudies-literatureMedial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.PMC9900470Wang SXLi JBZhang NLiang SQGuo RLiu XTang LLLuo WJHuang SHLiu LZXie FYLv JWChen LXu CLi YJZhou GQLi WFSun YLiang XYChen YPMao YPZhang YMa JGao TSLin LfalseMedial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.<h4>Objectives</h4>To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma.<h4>Design</h4>Open-label, non-inferiority, multicentre, randomised, phase 3 trial.<h4>Setting</h4>Three Chinese hospitals between 20 November 2017 and 3 December 2018.<h4>Participants</h4>Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement.<h4>Interventions</h4>Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer Center. Eligible patients were randomly assigned (1:1; block size of four) to receive MRLN sparing radiothe2023-01-01T00:00:00Z2023 Feb2026-05-28T20:15:16.216Z2025-04-05T11:23:57.121ZS-EPMC99004703674645910.1136/bmj-2022-072133